home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

59.33 -0.49 (-0.83%)

Streaming Delayed Price Updated: 2:40 PM EDT, Mar 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results

November 01, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences

November 01, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases

October 25, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases

October 12, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia

September 30, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences

September 29, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Earns $10 Million Phase 1 Milestone Payment

September 28, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

September 01, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals, inc (ARWR) Q3 2021 Earnings Call Transcript ↗

August 06, 2021

ARWR earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Recap: Arrowhead Pharmaceuticals Q3 Earnings ↗

August 05, 2021

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08%...

Via Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results

August 05, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

July 29, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals: Buy the Dip? ↗

July 19, 2021

This biotech underdog offers more than meets the eye.

Via The Motley Fool

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results

July 14, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 14, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Russell 2000 Traders Place Bearish Bets Via IWM ETF ↗

July 13, 2021

The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM...

Via Benzinga

Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright ↗

July 06, 2021

The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:

Via Benzinga

Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer ↗

July 06, 2021

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell...

Via Benzinga

Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

July 06, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher ↗

July 02, 2021

Toward the end of trading Friday, the Dow traded up 0.46% to 34,792.90 while the NASDAQ rose 0.67% to 14,619.12. The S&P also rose, gaining 0.66% to 4,348.47. The U.S. has the...

Via Benzinga

Topics Stocks

56 Biggest Movers From Friday ↗

July 06, 2021

Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70. Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 73.2% to close at $18.79. A 13G...

Via Benzinga

S&P 500 Logs Another Record High as "Fear Gauge" Dips ↗

July 02, 2021

Stocks are modestly in the black midday, thanks to upbeat monthly jobs data that showed 850,000 jobs were added in June.

Via Talk Markets

Topics Stocks

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 02, 2021

Gainers Alector (NASDAQ:ALEC) shares moved upwards by 52.47% to $34.17 during Friday's regular session. Alector's stock is trading at a volume of 26.9 million...

Via Benzinga

Arrowhead Stock Plunges, Alector Stock Surges On Drug News ↗

July 02, 2021

Arrowhead paused a drug study; Alector teamed up with GlaxoSmithKline to develop two drugs. Arrowhead stock sank, while Alector stock surged.

Via Investor's Business Daily

Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet ↗

July 02, 2021

Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to 4,340.12. The U.S. has the...

Via Benzinga

Topics Stocks

Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today ↗

July 02, 2021

A paused clinical trial with an important asset wasn't what investors wanted to hear today.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 02, 2021

Gainers Alector (NASDAQ:ALEC) stock moved upwards by 39.93% to $31.36 during Friday's pre-market session. The market value of their outstanding shares is at $2.5...

Via Benzinga

Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models ↗

July 02, 2021

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the...

Via Benzinga

Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

July 02, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

June 30, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com